Valiant Labs Reports ₹134.9 Crore Q2 FY27 Revenue Growth

Valiant Laboratories Limited reported Q2 FY27 revenue of ₹134.9 crore, up 112% year-on-year, as its board approved audited standalone and consolidated results for the quarter and half-year ended September 30, 2026, on November 2, 2026. The approval gives shareholders audited financial disclosures for the latest reporting period.

What did Valiant Labs approve on November 2, 2026?

Valiant Labs approved the audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The audit committee reviewed the quarterly results before they were placed before the board, which then reviewed and accepted them.

The filing includes financial tables for standalone and consolidated operations, comparative figures for prior periods, and the auditor's report. This matters because audited half-yearly results provide a formally reviewed view of the company's financial position, performance and disclosures for the six months to September 2026.

The company had informed exchanges on October 27 that its board would meet on November 2 to consider the Q2 and half-year FY27 results. It had also closed its trading window for insider transactions from October 1 until 48 hours after the release of the September-quarter results, in line with its code of conduct and applicable SEBI requirements.

How did Valiant Labs perform in Q2 FY27?

Valiant Labs reported Q2 FY27 revenue of ₹134.9 crore, representing 112% year-on-year growth, according to the supplied results information. The reported increase follows strong growth in the June 2026 quarter, when consolidated net sales were ₹115.29 crore, up 146.22% from ₹46.82 crore a year earlier.

A separate Q2 results summary stated that the company recorded consolidated net profit of ₹20.01 crore for the quarter ended September 30. That summary put total income at ₹470.68 crore and revenue from operations at ₹462.02 crore. The supplied material does not provide sufficient detail to reconcile this presentation with the ₹134.9 crore Q2 FY27 revenue figure, so investors should refer to the audited standalone and consolidated statements for the applicable basis of reporting.

The available information also records that the company paid fines of ₹2,11,800 each to BSE and NSE for delayed disclosure of a Rights Issue Committee meeting. The board has said it considers that non-compliance matter resolved.

What does the audited filing say about Valiant Labs' operations?

Valiant Labs has confirmed that it operates as a single segment in chemical manufacturing. This means the company has not presented separate operating segments in the results, and readers should assess its reported financial performance as relating to its chemical manufacturing business rather than a group of separately disclosed business lines.

The filing's standalone and consolidated formats remain important because the company has subsidiary operations. Standalone statements reflect the parent entity, while consolidated statements include the financial effects of subsidiaries. Differences between the two sets of numbers can arise from subsidiary revenue, costs, depreciation, finance costs and other consolidation adjustments.

The auditor's report accompanying the results is another central part of the disclosure. It provides audit-related validation of the financial statements presented for the period, while the board approval records the company's formal governance process for releasing the figures to shareholders and stock exchanges.

What was Valiant Labs' financial position before the September quarter?

Valiant Labs entered the September quarter after a marked improvement in the June 2026 results. For Q1 FY27, consolidated revenue was reported at ₹116.15 crore and consolidated net income at ₹21.10 crore. Basic and diluted earnings per share were ₹3.89, compared with ₹0.42 in the corresponding quarter a year earlier.

On a standalone basis, the company reported Q1 FY27 revenue from operations of ₹74.27 crore, up 44% year-on-year, and net profit of ₹9.48 crore, up 422% from ₹1.82 crore in Q1 FY26. The figures indicate that the September-quarter disclosure came after a stronger first quarter across the group and parent-company presentations.

For FY26, Valiant Labs reported standalone revenue of ₹217.04 crore, up 62.75%, and standalone profit after tax of ₹5.55 crore, compared with a loss of ₹2.15 crore in the prior year. Consolidated revenue for FY26 was ₹237.47 crore, while consolidated profit after tax remained a loss of ₹3.27 crore, with depreciation and finance costs cited in the supplied information.

How do the results affect investors and the company?

The audited results give investors a more complete basis for tracking the company's first-half FY27 performance, particularly after the growth reported in the June quarter. Revenue growth is relevant because the supplied information linked the first-quarter improvement in profitability and margin to higher revenue.

For shareholders, the distinction between standalone and consolidated performance remains significant. The FY26 data showed that the parent company returned to standalone profitability while the consolidated business reported a loss. The audited September-quarter statements can therefore help investors evaluate whether revenue expansion and profitability are developing consistently across the group.

The disclosure also keeps governance issues in focus. While the board considers the delayed disclosure matter resolved after payment of the BSE and NSE fines, exchange-compliance disclosures remain relevant for investors assessing the company's reporting processes alongside its operating and financial performance.

Conclusion

Valiant Labs has completed the formal approval and audit process for its Q2 and first-half FY27 financial statements, with reported Q2 FY27 revenue of ₹134.9 crore, up 112% year-on-year. The update follows a strong June quarter and provides shareholders with audited standalone and consolidated disclosures, while also documenting the company's single-segment chemical manufacturing structure.

Investors should watch the detailed audited statements for the respective standalone and consolidated revenue, profit and cash-flow trends for the half year. They should also monitor subsequent exchange filings for continued compliance disclosures and for clarity on how the company's growth, depreciation and finance costs affect consolidated profitability.